Медицинская библиотека · Prostate cancer and prostatic diseases · 2025

DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis.

Yu Evan Y, Suzuki Hiroyoshi, Pieczonka Christopher M, Gotto Geoffrey, Briganti Alberto, Luz Murilo, Murphy Declan, Malone Ryan, Hamilton Joelle, Chan Jonathan E, Sieber Paul, Given Robert W, Hellmis Eva, Kretz Thomas, Spiegelhalder Philipp, Gómez-Caamaño Antonio, Amela Yaovi Messan, Artignan Xavier, Uemura Hiroji, Fujita Naoki, Adorjan Patrick, Ghadessi Mercedeh, Verholen Frank, Armstrong Andrew J

СтатьяНаблюдательное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

DAROL is an ongoing study of real-world safety and effectiveness of darolutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).

SUBJECTS/

METHODS

This prespecified interim analysis included 550 patients with nmCRPC who completed ≥6 months of treatment with darolutamide 600 mg twice daily.

RESULTS

Darolutamide showed consistent safety and effectiveness in DAROL vs ARAMIS. Most treatment-emergent adverse events were grade 1/2. Two-year overall survival and metastasis-free survival rates and prostate-specific antigen responses were similar to ARAMIS.

CONCLUSIONS

These findings indicate that darolutamide offers effectiveness and a favorable safety profile in the broad range of patients seen in clinical practice.

Для цитирования: Yu Evan Y, Suzuki Hiroyoshi, Pieczonka Christopher M, Gotto Geoffrey, Briganti Alberto, Luz Murilo, Murphy Declan, Malone Ryan, Hamilton Joelle, Chan Jonathan E, Sieber Paul, Given Robert W, Hellmis Eva, Kretz Thomas, Spiegelhalder Philipp, Gómez-Caamaño Antonio, Amela Yaovi Messan, Artignan Xavier, Uemura Hiroji, Fujita Naoki, Adorjan Patrick, Ghadessi Mercedeh, Verholen Frank, Armstrong Andrew J. DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis.. Prostate cancer and prostatic diseases. 2025. DOI: 10.1038/s41391-025-01047-7.

Предметные рубрики MeSH

Humans Male Prostatic Neoplasms, Castration-Resistant Aged Middle Aged Pyrazoles Prostate-Specific Antigen Aged, 80 and over Treatment Outcome

Подготовка и перевод публикации

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.